Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Med Chem ; 268: 116263, 2024 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-38432056

RESUMO

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related variants, are responsible for the devastating coronavirus disease 2019 (COVID-19) pandemic. The SARS-CoV-2 main protease (Mpro) plays a central role in the replication of the virus and represents an attractive drug target. Herein, we report the discovery of novel SARS-CoV-2 Mpro covalent inhibitors, including highly effective compound NIP-22c which displays high potency against several key variants and clinically relevant nirmatrelvir Mpro E166V mutants.


Assuntos
COVID-19 , Peptidomiméticos , Humanos , Peptidomiméticos/farmacologia , Peptídeo Hidrolases , Inibidores de Proteases/farmacologia , SARS-CoV-2 , Cisteína Endopeptidases , Antivirais/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA